Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.38 |
| ▸ | GAA | P10253 | 7/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.31 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69183 | 0.81 | CLK1 (0.36) | CYP3A4TSHRALDH1A1KMT2AHPGD | |
| SCHEMBL16535224 | 0.81 | PIM1 (0.37) | TSHRALDH1A1MAPTKMT2APOLB | |
| SCHEMBL1693909 | 0.80 | POLB (0.34) | ALDH1A1KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL1860331 | 0.78 | FGFR4 (0.41) | KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL1861969 | 0.78 | POLB (0.35) | KMT2APOLBL3MBTL1MEN1 | |
| SCHEMBL17409605 | 0.77 | RXRA (0.34) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16535487 | 0.76 | HCRTR1 (0.37) | POLBGRM5 | |
| SCHEMBL3770744 | 0.73 | LMNA (0.33) | ALDH1A1SMN1; SMN2KMT2ALMNA | |
| SCHEMBL5261037 | 0.73 | LMNA (0.49) | TSHRALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL1819971 | 0.72 | POLB (0.55) | TSHRALDH1A1GAASMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107428744-B | Novel heterocyclic compounds and their use in medicine and cosmetics | 盖尔德马研究及发展公司 | 2021-09-24 | — | — | CN | disclosed |
| EP-2326639-B1 | SUBSTITUTED PYRIDINES AND ITS USE AS GSK3 INHIBITORS | BAYER IP GMBH (DE) | 2015-08-19 | — | — | EP | disclosed |
| EP-2280976-B1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER IP GMBH (DE) | 2014-01-01 | — | — | EP | disclosed |
| US-8436003-B2 | Substituted imidazo- and triazolopyrimidines, imidazo- and pyrazolopyrazines and imidazotriazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-07 | — | — | US | disclosed |
| EP-1799672-B1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-02 | — | — | EP | disclosed |
| EP-2176264-B1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES FOR TREATING HEMATOLOGICAL DISORDERS | BAYER IP GMBH (DE) | 2012-12-19 | — | — | EP | disclosed |
| EP-2137188-B1 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | Bayer Pharma AG (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-8110575-B2 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-07 | — | — | US | disclosed |
| US-8039460-B2 | CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headache; compounds based on 6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine or 6,7,8,9-tetrahydro-5H-imidazo[1,2-a]azepine | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20110224201-A1 | CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-09-15 | — | — | US | disclosed |
| WO-2010012398-A1 | SUBSTITUTED PYRIDINES, AND USE THEREOF AS GSK3 INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | WO | disclosed |
| EP-2137188-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-12-30 | — | — | EP | disclosed |
| WO-2009138176-A1 | SUBSTITUTED IMIDAZO- AND TRIAZOLOPYRIMIDINES, IMIDAZO- AND PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AS GSK3BETA-INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-19 | — | — | WO | disclosed |
| WO-2009074259-A1 | TRIAZOLOTRIAZINES AND TRIAZOLOPYRAZINES AND THE USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009007029-A1 | IMIDAZO-, PYRAZOLOPYRAZINES AND IMIDAZOTRIAZINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008113469-A2 | SUBSTITUTED IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-25 | — | — | WO | disclosed |
| US-7288655-B2 | α v integrin receptor antagonists | MERCK & CO., INC. (US) | 2007-10-30 | — | — | US | disclosed |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2006-07-06 | — | — | US | disclosed |
| EP-1603906-A2 | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ALPHA V BETA 3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078109-A2 | PROCESS FOR SYNTHESISING USEFUL INTERMEDIATES FOR THE PREPARATION OF ανβ3 RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224201-A1 | CGRP RECEPTOR ANTAGONISTS | CCKAR, CALCRL, QRFPR | CYP3A4 2216/4885TSHR 350/4885ALDH1A1 2464/4885 |
| US-20060149069-A1 | Process for synthesising useful intermediates for the preparation of avss3 receptor antagonists | AVPR1A, AVPR1B, ADRB3 | CYP3A4 694/4885TSHR 334/4885ALDH1A1 2551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.